IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ITP IT Tech Packaging Inc

Market Closed 04-17 16:00:00 EDT

0.2040

+0.0040

+2.00%

盘后0.1941

-0.0099-4.85%

19:59 EDT

High0.2099	Low0.1883	Vol2.12M
Open0.1931	D1 Closing0.2000	Amplitude10.80%
Mkt Cap3.46M	Tradable Cap3.35M	Total Shares16.97M
T/O416.43K	T/O Rate12.91%	Tradable Shares16.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ITP","market":"US","secType":"STK","nameCN":"IT Tech Packaging Inc","latestPrice":0.204,"timestamp":1776456000000,"preClose":0.2,"halted":0,"volume":2120261,"hourTrading":{"tag":"盘后","latestPrice":0.1941,"preClose":0.204,"latestTime":"19:59 EDT","volume":23194,"amount":4550.95375,"timestamp":1776470379842,"change":-0.0099,"changeRate":-0.048529,"amplitude":0.062745},"delay":0,"changeRate":0.01999999999999988,"floatShares":16423703,"shares":16965420,"eps":-0.861876,"marketStatus":"Market Closed","change":0.004,"latestTime":"04-17 16:00:00 EDT","open":0.1931,"high":0.209899,"low":0.1883,"amount":416433.74178263004,"amplitude":0.107995,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.861876,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776672000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"AMEX","adjPreClose":0.2,"preHourTrading":{"tag":"盘前","latestPrice":0.1884,"preClose":0.2,"latestTime":"09:28 EDT","volume":276333,"amount":52059.22773897,"timestamp":1776432484135,"change":-0.0116,"changeRate":-0.058,"amplitude":0.0595},"postHourTrading":{"tag":"盘后","latestPrice":0.1941,"preClose":0.204,"latestTime":"19:59 EDT","volume":23194,"amount":4550.95375,"timestamp":1776470379842,"change":-0.0099,"changeRate":-0.048529,"amplitude":0.062745},"volumeRatio":0.16443913195751325,"impliedVol":0.0783,"impliedVolPercentile":0.048},"requestUrl":"/m/hq/s/ITP/wiki","defaultTab":"wiki","newsList":[{"id":"2625949158","title":"Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625949158","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625949158?lang=en_us&edition=fundamental","pubTime":"2026-04-08 19:00","pubTimestamp":1775646000,"startTime":"0","endTime":"0","summary":"WELLESLEY HILLS, Mass., April  08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/08/3269976/0/en/Climb-Bio-to-Host-R-D-Spotlight-Webcast-Highlighting-Budoprutug-and-the-CD19-Opportunity-on-May-5-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HST","BK4199","BK4218","BK4181","SLE","ITP","BK4588","BK4077","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624755447","title":"IT Tech Packaging delays filing annual report, cites unfinished financial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2624755447","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624755447?lang=en_us&edition=fundamental","pubTime":"2026-04-01 08:03","pubTimestamp":1775001793,"startTime":"0","endTime":"0","summary":"IT Tech Packaging flagged a delay in filing its annual report on Form 10-K for fiscal year ended Dec. 31, 2025.Filing missed deadline as company had not finalized financial results or required disclosures.Company expects to file Form 10-K within 15 calendar days of prescribed due date.Management does not anticipate a significant change in results versus prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IT Tech Packaging Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL7QlHHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623589931","title":"3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2623589931","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623589931?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:13","pubTimestamp":1774959180,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc.  today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a high-quality performance with both quantitative and qualitative growth: annual revenue hit RMB 17.7 billion, a historic breakthrough past the RMB 10 billion mark, representing a 94.3% year-on-year  increase; net profit attributable to shareholders of the parent company reached RMB 8.48 billion, surging 305.8% YoY; adjusted net profit attributable to shareholders of the parent company stood at RMB 8.45 billion, a 264.6% YoY rise. The company's profitability achieved a leap-forward growth, demonstrating robust growth momentum.Under the collaboration agreement, 3SBio granted Pfizer exclusive global development and commercialization rights to SSGJ-707, with the total potential deal value exceeding US$6 billion. The company is also entitled to tiered double-digi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/3sbio-announces-2025-annual-results-dual-engines-of-innovative-rd-and-global-collaboration-propel-revenue-past-rmb-10-billion-milestone-302729335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999003800.SGD","SG9999002232.USD","IND.AU","ITP","BK4581","LU0321505439.SGD","LU1883839398.USD","HK0000165453.HKD","SG9999011175.SGD","BK4585","BK4007","LU0456855351.SGD","IE000M9KFDE8.USD","BK7095","IE00B19Z3B42.SGD","LU0985481810.HKD","LU1066053197.SGD","SG9999001176.USD","IE00BLSP4452.SGD","BRVO","BK4599","BK4218","BK4181","BK1583","BK4592","SAA","IE00B19Z3581.USD","LU0321505868.SGD","IE0002270589.USD","IBD","01530","LU0306806265.USD","LU1894683264.USD","SG9999013999.USD","BK4534","BK1161","BK1593","BK4568","SLE","BK4588","BK7016","LU0289739699.SGD","IND","LU0170899867.USD","LU0225284248.USD","BK4077","PFE","LU1894683348.USD","CLDT","ADA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623370691","title":"Press Release: Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2623370691","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623370691?lang=en_us&edition=fundamental","pubTime":"2026-03-31 13:30","pubTimestamp":1774935000,"startTime":"0","endTime":"0","summary":"New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos. Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities. Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig. Management to host conference call today, March 31, 2026, at 14:00 CET / 8:00 am ET. Gamgertamig  is a clinical--stage BCMAxCD3 T cell engager designed to enable rapid and deep plasma and B--cell depletion following a short duration, subcutaneously administered treatment course. In ongoing Phase 1/2 clinical studies, gamgertamig has demonstrated transformative efficacy and a differentiated safety profile after a single treatment cycle in severe antibody-mediated orphan diseases, including autoimmune hemolytic anemia  and immune thrombocytopenia . Gamgertamig has been granted both Fast Track ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","GLPG","BK4139","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315283","title":"InnoCare Hits Profit Milestone, Relative Undervaluation Points To Stock Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315283","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315283?lang=en_us&edition=fundamental","pubTime":"2026-03-30 17:48","pubTimestamp":1774864080,"startTime":"0","endTime":"0","summary":"The innovative drugmaker's newfound profitability marks its transition into a new stage characterized by stability and virtuous development cycles. Despite attracting strong market attention for its big business development deals, the company remains relatively undervalued. InnoCare now stands at a \"triple inflection point,\" with profitability achieved, globalization enhanced, and core pipelines progressed, marking a new stage in its development.InnoCare also differs from some of its peers that achieved early profitability by relying on one-time upfront payments from partnerships. By comparison, InnoCare's march to profitability has been jointly propelled by a dual engine of licensing deals and direct product sales. On the commercial front, the company's drug sales reached 1.44 billion yuan last year, up 43.4%.Orelabrutinib continued its strong momentum, now included on China's National Reimbursement Drug List for all four of its indications. Its approval as a first-line treatment for ","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/30/-30-3-2026-101148-thebambooworks-com.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/30/-30-3-2026-101148-thebambooworks-com.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/26/03/51532367/innocare-hits-profit-milestone-relative-undervaluation-points-to-stock-upside","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/Opinion/26/03/51532367/innocare-hits-profit-milestone-relative-undervaluation-points-to-stock-upside","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0006306889.USD","LU2357305700.SGD","BK4581","LU1668664300.SGD","LU0158827781.USD","LU2347655156.SGD","LU0106831901.USD","LU1244550494.USD","LU2023251221.USD","BK4199","LU0320765646.SGD","LU1244550577.SGD","LU1162221912.USD","LU0314104364.USD","LU1791710400.SGD","LU0267386448.USD","LU1244550221.USD","LU0912757837.SGD","LU1732800096.USD","LU0795875169.SGD","LU1989772840.SGD","BK4534","LU0795875086.SGD","LU2089284900.SGD","LU2089283258.USD","LU2028103732.USD","LU1074936037.SGD","LU0098860793.USD","PCOM","LU0882574139.USD","LU0106261372.USD","LU0971096721.USD","LU2133065610.SGD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0557290698.USD","BK4504","LU1548497426.USD","BK4516","LU1363072403.SGD","LU1791710582.SGD","BK4077","BK4122","LU1720051017.SGD","LU1720051108.HKD","LU2111349929.HKD","LU1989772923.USD","SLE","ITP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621081422","title":"Press Release: Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621081422","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621081422?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:05","pubTimestamp":1774296300,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 23, 2026  -- Bionano Genomics, Inc.  today reported financial results for the fourth quarter and full year ended December 31, 2025.For the three-month period ended December 31, 2025, as compared to the same period of 2024:. -- Reported total revenue of $8.0 million, representing a decrease of 3%. from $8.2 million in the fourth quarter of 2024.-- The prior year period included $2.8 million in instrument revenue,compared to $2.7 million in the fourth quarter of 2025.-- Sold 7,554 nanochannel array flowcells in the fourth quarter of 2025,representing a decrease of 6% over the 8,058 flowcells sold in the fourth. -- Installed 9 new OGM systems and brought 6 back to reach an installed base. of 387 at quarter-end, representing a 4% increase over the 371 installed. systems reported at the end of the fourth quarter of 2024.-- Generated gross margin of 43%, compared to 42% for the fourth quarter of. 2024, and non-GAAP gross margin1 of 43%, compared to 42% for the fourth. -- Rep","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4585","BK4199","LU0738911758.USD","CMS","03160","LU0545039389.USD","BK4121","BK4588","LU1894683348.USD","ITP","LU2500361329.USD","LU0949170772.SGD","TM","LU1003077747.HKD","BK4604","BK4555","LU1894683264.USD","LU0661504455.SGD","LU2637428348.USD","BK4575","BNGO","LU0553294199.USD","LU2346227817.USD","BK4208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620460844","title":"Argenx’s Long‑Term ITP Study Reaches Completion, Sharpening the Outlook for Efgartigimod","url":"https://stock-news.laohu8.com/highlight/detail?id=2620460844","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620460844?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:30","pubTimestamp":1773678613,"startTime":"0","endTime":"0","summary":"Argenx ($ARGX) announced an update on their ongoing clinical study. Argenx’s latest update covers a long‑term Phase 3 trial of efgartigimod in adul...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/argenxs-long‑term-itp-study-reaches-completion-sharpening-the-outlook-for-efgartigimod?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/argenxs-long‑term-itp-study-reaches-completion-sharpening-the-outlook-for-efgartigimod?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ITP","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617411075","title":"Press Release: Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2617411075","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617411075?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:00","pubTimestamp":1772712000,"startTime":"0","endTime":"0","summary":"Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026. Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026. Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026. WELLESLEY HILLS, Mass., March 05, 2026  -- Climb Bio, Inc. , a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates.previously treated patients with ITP is designed to evaluate safety,","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","IND","ASH","BK4139","LU2463526074.USD","BK4077","CLYM","BK4539","ITP","BK4109","SLE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614859660","title":"Bionano Symposium 2026 Concluded with 9 Speakers Describing the Breadth of Bionano Solutions and Their Potential for Use on a Large Scale","url":"https://stock-news.laohu8.com/highlight/detail?id=2614859660","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614859660?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:00","pubTimestamp":1772197200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  27, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/27/3246483/0/en/Bionano-Symposium-2026-Concluded-with-9-Speakers-Describing-the-Breadth-of-Bionano-Solutions-and-Their-Potential-for-Use-on-a-Large-Scale.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4179","VIA","ITP","BK4199","CN","NGS","BK4081","BK4023","VGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614044496","title":"10 Presentations on Day 3 of Bionano Symposium 2026 Showcase OGM’s Utility in Unraveling the Complex Puzzles of Constitutional Genetic Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2614044496","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614044496?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:00","pubTimestamp":1772110800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  26, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitledOGM Making its Mark in Constitutional Gene","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245500/0/en/10-Presentations-on-Day-3-of-Bionano-Symposium-2026-Showcase-OGM-s-Utility-in-Unraveling-the-Complex-Puzzles-of-Constitutional-Genetic-Disorders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","BK4211","BK4196","BK4588","CMA","BK4199","ITP","BK4144","BK4585","WGS","WES","BK4590","BK4589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614807018","title":"argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614807018","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614807018?lang=en_us&edition=fundamental","pubTime":"2026-02-26 14:00","pubTimestamp":1772085600,"startTime":"0","endTime":"0","summary":"$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% yearoveryear growth Delivered $1.1 billion in operating income in 2025, marking first year of op","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245199/0/en/argenx-Reports-Full-Year-2025-Financial-Results-and-Provides-Fourth-Quarter-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0553294199.USD","BK4023","GD","BK4550","LU1894683264.USD","BK4199","LU0545039389.USD","BK4566","LU2500361329.USD","PFS","BK4208","LU2637428348.USD","BK4195","LU0949170772.SGD","BK4585","LU1894683348.USD","LU0170899867.USD","BK4187","LU0738911758.USD","BK4516","BK4588","CMS","BK4211","LU1003077747.HKD","LU0661504455.SGD","LU2346227817.USD","ITP","PRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613714299","title":"9 Presentations Kick Off Day 1 of the Bionano Symposium 2026 Covering Advances in Optical Genome Mapping for Hematologic Malignancies","url":"https://stock-news.laohu8.com/highlight/detail?id=2613714299","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613714299?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:00","pubTimestamp":1771938000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 1 of the Bionano Symposium 2026 entitled Advancements in Hematologic Malignanci","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3243479/0/en/9-Presentations-Kick-Off-Day-1-of-the-Bionano-Symposium-2026-Covering-Advances-in-Optical-Genome-Mapping-for-Hematologic-Malignancies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4179","OCC","BK4115","BK4020","LU0541502299.USD","LU0541501648.USD","NGS","BK4199","ITP","KT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610656991","title":"Bionano Announces Bionano Symposium 2026: Global Experts Showcase Advances and Innovation in Optical Genome Mapping","url":"https://stock-news.laohu8.com/highlight/detail?id=2610656991","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610656991?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:05","pubTimestamp":1770645900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  09, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced Bionano Symposium 2026, the premier global event for the optical genome mapping (OGM) community. Th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/09/3234612/0/en/Bionano-Announces-Bionano-Symposium-2026-Global-Experts-Showcase-Advances-and-Innovation-in-Optical-Genome-Mapping.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4020","ITP","BK4199","OCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609998473","title":"Takeda’s Mezagitamab ITP Extension Study: Long-Term Data That Matters for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2609998473","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609998473?lang=en_us&edition=fundamental","pubTime":"2026-02-05 00:32","pubTimestamp":1770222764,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clinical study. Study Overview: Takeda is running a Phase 3 continuation ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takedas-mezagitamab-itp-extension-study-long-term-data-that-matters-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takedas-mezagitamab-itp-extension-study-long-term-data-that-matters-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","ITP","BK4199","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608605362","title":"Bionano Announces Publication from Sanford Burnham Prebys Medical Discovery Institute Describing use of OGM to Detect Genomic Alterations Introduced by Gene Editing Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2608605362","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608605362?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:00","pubTimestamp":1770210000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  04, 2026  (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced a peer-reviewed study published in Molecular Therapy - Methods & Clinical Development, describing the app","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3232006/0/en/Bionano-Announces-Publication-from-Sanford-Burnham-Prebys-Medical-Discovery-Institute-Describing-use-of-OGM-to-Detect-Genomic-Alterations-Introduced-by-Gene-Editing-Technologies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ITP","BK4199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602543576","title":"CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543576","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543576?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:36","pubTimestamp":1768224960,"startTime":"0","endTime":"0","summary":"-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216929/0/en/CRISPR-Therapeutics-Highlights-Strategic-Priorities-and-Anticipated-2026-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0868494708.USD","CRSP","IE00BSNM7G36.USD","LU0942090050.USD","LU1064131342.USD","BK4588","SLE","CAT","LU1917777945.USD","IE00BD6J9T35.USD","BK4556","LU0963586101.USD","BK4077","LU1974910355.USD","FXI","BK4516","BK4611","LU2264538146.SGD","LU0742534661.SGD","BK4149","LU1861559042.SGD","BK4230","BK4153","BK4532","ITP","SCD","LU2106854487.HKD","TG","BK4090","LU2357305700.SGD","LU0048573561.USD","LU1720051017.SGD","BK4022","LU1720051108.HKD","BK4504","LU0868494617.USD","BK4520","LU0251142724.SGD","LU2237438978.USD","AGT","BK4597","LDL","LU1861558580.USD","BK4199","CAR","LU0251131958.USD","LU1548497426.USD","LU2023250504.SGD","LU1988902786.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602108435","title":"Press Release: Bionano Reports Preliminary Fourth Quarter and Full-Year 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2602108435","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602108435?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222800,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan. 12, 2026  -- Bionano Genomics, Inc.  today reported certain unaudited preliminary financial results and commercial highlights for the fourth quarter and fiscal year ended December 31, 2025.Fourth Quarter 2025 Preliminary, Unaudited Financial and Business Results. -- Total revenue is expected to be in the range of $7.8 million to $8.0. million, which is at the upper end of guidance and represents a decrease. in the range of 2% to 4% year-over-year.-- Nanochannel array flowcells sold in the fourth quarter of 2025 is. -- Total revenue is expected to be in the range of $28.4 million to $28.6. represents a decrease in the range of 7% to 8% year-over-year.resulted in an installed base of 387 OGM systems at year-end 2025,Cash, cash equivalents, available-for-sale securities, and restricted short-term investments were approximately $29.6 million as of December 31, 2025, of which $10.3 million is subject to certain restrictions.Bionano is in the process of completing its customa","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP","BK4555","BK4099","03160","BK4585","BNGO","BK4575","BK4121","TM","BK4588","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602595531","title":"argenx Highlights 2026 Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2602595531","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602595531?lang=en_us&edition=fundamental","pubTime":"2026-01-12 14:00","pubTimestamp":1768197600,"startTime":"0","endTime":"0","summary":"Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales  VYVGART impact continues with approximately 19,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216531/0/en/argenx-Highlights-2026-Strategic-Priorities.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMS","LU2500361329.USD","BK4566","BK4588","BK4585","LU0553294199.USD","LU0738911758.USD","LU1894683264.USD","LU0170899867.USD","LU2637428348.USD","BK4208","LU0545039389.USD","BK4217","BK4550","GD","LU1894683348.USD","LU0661504455.SGD","LU2346227817.USD","LU1003077747.HKD","BK4187","SMA","ITP","BK4199","BK4516","LU0949170772.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601698403","title":"Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601698403","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601698403?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873600,"startTime":"0","endTime":"0","summary":"First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215211/0/en/Climb-Bio-Announces-Pipeline-Progress-and-Strategic-Priorities-for-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","BK4077","SLE","BK4109","LU2463526074.USD","BK4199","PRGS","ITP","LU2065732104.USD","BK4097","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163901175","title":"Hangzhou's \"Six Little Dragons\" See Another IPO Emerge","url":"https://stock-news.laohu8.com/highlight/detail?id=1163901175","media":"Deep News","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163901175?lang=en_us&edition=fundamental","pubTime":"2026-01-05 15:41","pubTimestamp":1767598901,"startTime":"0","endTime":"0","summary":"Investing hinges on the insights of Golden Kirin analyst reports, which offer authority, professionalism, timeliness, and comprehensiveness to help you uncover potential thematic opportunities! The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","ITP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.itpackaging.cn","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.1178},{"period":"3month","weight":-0.1138},{"period":"6month","weight":-0.227},{"period":"1year","weight":-0.2302},{"period":"ytd","weight":-0.0672}],"compareEarnings":[{"period":"1week","weight":0.0452},{"period":"1month","weight":0.0736},{"period":"3month","weight":0.0267},{"period":"6month","weight":0.0689},{"period":"1year","weight":0.349},{"period":"ytd","weight":0.0414}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"IT Tech Packaging, Inc., together with its subsidiaries, engages in the production and distribution of paper products in the People's Republic of China. The company operates through three segments: Dongfang Paper, Tengsheng Paper, and Baoding Shengde. It offers corrugating medium papers to companies making corrugating cardboards; and offset printing papers to printing companies. The company also provides tissue paper products, including toilet papers, boxed and soft-packed tissues, handkerchief tissues, and paper napkins, as well as bathroom and kitchen paper towels under the Dongfang Paper brand. In addition, it produces and sells non-medical single-use face masks, and medical face masks. The company was formerly known as Orient Paper, Inc. and changed its name to IT Tech Packaging, Inc. in August 2018. The company is headquartered in Baoding, the People's' Republic of China.","yearOnYearQuotes":[{"month":1,"riseRate":0.411765,"avgChangeRate":0.000296},{"month":2,"riseRate":0.352941,"avgChangeRate":-0.00011},{"month":3,"riseRate":0.176471,"avgChangeRate":-0.025315},{"month":4,"riseRate":0.352941,"avgChangeRate":0.045405},{"month":5,"riseRate":0.3125,"avgChangeRate":-0.119651},{"month":6,"riseRate":0.3125,"avgChangeRate":-0.03945},{"month":7,"riseRate":0.466667,"avgChangeRate":-0.042617},{"month":8,"riseRate":0.125,"avgChangeRate":-0.076512},{"month":9,"riseRate":0.4375,"avgChangeRate":0.011462},{"month":10,"riseRate":0.375,"avgChangeRate":0.03598},{"month":11,"riseRate":0.375,"avgChangeRate":0.097377},{"month":12,"riseRate":0.125,"avgChangeRate":0.001262}],"exchange":"AMEX","name":"IT Tech Packaging Inc","nameEN":"IT Tech Packaging Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IT Tech Packaging Inc,ITP,IT Tech Packaging Inc股票,IT Tech Packaging Inc股票老虎,IT Tech Packaging Inc股票老虎国际,IT Tech Packaging Inc行情,IT Tech Packaging Inc股票行情,IT Tech Packaging Inc股价,IT Tech Packaging Inc股市,IT Tech Packaging Inc股票价格,IT Tech Packaging Inc股票交易,IT Tech Packaging Inc股票购买,IT Tech Packaging Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IT Tech Packaging Inc(ITP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IT Tech Packaging Inc(ITP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction